Enlivex Therapeutics Fights Back Against False News Report

Enlivex Therapeutics Ltd. (Nasdaq and TASE: ENLV), a clinical-stage macrophage reprogramming immunotherapy company, has issued an urgent statement addressing a false news report published by Tipranks.com. The report claimed that the company had suspended its stock trading due to an internal investigation, which the company unequivocally denies. This incident highlights the challenges faced by small-cap biotech companies in maintaining investor confidence and protecting their reputations in the face of market manipulation.

The false report, published on February 18, 2025, alleged that Enlivex Therapeutics had suspended its stock trading due to an internal investigation. The company swiftly responded by issuing a statement, refuting the claims and assuring investors that its shares continue to trade regularly on both the Tel Aviv Stock Exchange and NASDAQ Stock Exchange without any interruption. CEO Oren Hershkovitz characterized the incident as a blatant attempt to manipulate public perception and mislead investors, stating that the company will pursue all available legal actions against the individuals responsible, including the publishers of the false report and the hosting service of Tipranks.com.



The incident serves as a reminder of the risks associated with investing in small-cap stocks, which are often more volatile and susceptible to market manipulation. Small-cap companies are particularly vulnerable to such attacks due to lower trading volumes and increased price sensitivity to news. In this case, the false report led to a sharp decline in Enlivex Therapeutics' stock price, which has decreased by -65.29% in the past year. However, the company's commitment to pursuing legal action against the responsible parties demonstrates its determination to protect its reputation and restore investor confidence.

The incident also raises concerns about the broader biotech sector, as investors may become more cautious when evaluating small-cap biotech stocks. However, the biotech sector as a whole is not likely to be significantly impacted, as Enlivex is a relatively small player in the market. The sector's fundamentals and long-term growth prospects remain intact.

In conclusion, the false news report published by Tipranks.com had a significant impact on Enlivex Therapeutics' short-term and long-term stock performance, as well as investor confidence in the company and the broader biotech sector. The company's swift and unequivocal denial, along with its commitment to pursuing legal action against the responsible parties, demonstrates its determination to protect its reputation and restore investor confidence. As small-cap biotech companies continue to face challenges in maintaining investor confidence and protecting their reputations, it is crucial for them to remain vigilant and take appropriate actions to address market manipulation attempts.